Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2021 Aug;10(4):534-537.
doi: 10.21037/hbsn-21-238.

Perioperative immunotherapy for pancreatic cancer is on its way

Christoph Springfeld  1 , Peter Bailey  2   3 , Thilo Hackert  2 , John P Neoptolemos  2
Affiliations
Editorial

Perioperative immunotherapy for pancreatic cancer is on its way

Christoph Springfeld et al. Hepatobiliary Surg Nutr. 2021 Aug.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://dx.doi.org/10.21037/hbsn-21-238). Dr. CS has received payments for lectures and advisory boards from Roche, MSD, Bayer, Servier, Astra Zeneca and Eisai. The other authors have no conflicts of interest to declare.

Comment on

References

    1. Klaiber U, Hackert T, Neoptolemos JP. Adjuvant treatment for pancreatic cancer. Transl Gastroenterol Hepatol 2019;4:27. 10.21037/tgh.2019.04.04 - DOI - PMC - PubMed
    1. Ghaneh P, Palmer DH, Cicconi S, et al. ESPAC-5F: Four-arm, prospective, multicenter, international randomized phase II trial of immediate surgery compared with neoadjuvant gemcitabine plus capecitabine (GEMCAP) or FOLFIRINOX or chemoradiotherapy (CRT) in patients with borderline resectable pancreatic cancer. J Clin Oncol 2020;38:4505. 10.1200/JCO.2020.38.15_suppl.4505 - DOI
    1. Imamura M, Doi R, Imaizumi T, et al. A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 2004;136:1003-11. 10.1016/j.surg.2004.04.030 - DOI - PubMed
    1. Hackert T, Sachsenmaier M, Hinz U, et al. Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients. Ann Surg 2016;264:457-63. 10.1097/SLA.0000000000001850 - DOI - PubMed
    1. Katz MHG, Shi Q, Meyers JP, et al. Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy (RT) for borderline resectable (BR) adenocarcinoma of the pancreas. J Clin Oncol 2021;39:377. 10.1200/JCO.2021.39.3_suppl.377 - DOI - PMC - PubMed